Navigation Links
Parkinson's patients who are pathological gamblers also display abnormal social behavior
Date:1/14/2010

People with Parkinson's Disease are more likely to display abnormal social behaviour and make poor decisions in ambiguous circumstances if they are pathological gamblers, according to research in the January issue of the European Journal of Neurology.

A number of studies have already associated pathological gambling with Parkinson's, suggesting that it is a frequent impulse control disorder associated mainly with dopamine replacement therapy.

Researchers from the Raul Carrea Institute for Neurological Research (FLENI) in Buenos Aires, Argentina, interviewed the immediate relatives of seven Parkinson's patients who were pathological gamblers. They also interviewed the families of 13 patients - matched by age, sex, education and disease severity - who did not gamble.

They found that the gamblers were less co-operative with others, had difficulties making or keeping close relationships and often did what they wanted, without caring what other people thought.

The researchers also found that the patients in the pathological gambling group performed worse in the Iowa Gambling Task, which is used to assess decision-making abilities in ambiguous or risky situations.

"The object of this study was to assess decision-making processes in Parkinson's Disease patients with and without pathological gambling by asking them and their relatives to take part in a series of tests" says Dr Ramon Leiguarda, an expert in cognitive neurology.

"We found that the patients in the pathological gambling group were more likely to make poor decisions and select disadvantageous alternatives more frequently than advantageous alternatives."

The combination of poor decision-making and abnormal social behaviour has led the team to conclude that dopamine replacement therapy can induce dysfunction in the areas of the brain that control affective decision making - the ventromedial pre-frontal cortex and amygdala-ventral striatum system.

Six of the seven pathological gamblers who took part in the study were male. At the time of the study they had an average age of 61 and their average age at diagnosis was 52.

Six of the patients had no history of gambling before developing Parkinson's Disease. One patient had played poker with friends for 30 years, but his gambling behaviour exacerbated after starting dopamine replacement therapy and now included roulette and horse racing.

The other six participants said that their preferred type of gambling was slot machines.

Four of the seven displayed other impulse control disorders - two were also compulsive shoppers and two displayed hypersexuality.

"We believe that the behaviour highlighted in our study, combined with previous research into the links between Parkinson's Disease and pathological gambling, point to dopamine replacement therapy causing dysfunction in specific areas of the brain" says Dr Leiguarda.

"Further studies that assess Parkinson's Disease patients recovering from pathological gambling are needed to better understand the physiopathology of this impulse control disorder."


'/>"/>

Contact: Annette Whibley
wizard.media@virgin.net
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
2. Comparison of obstetric outcomes between on-call and patients own obstetricians
3. Vision restoration therapy shown to improve brain activity in brain injured patients
4. Diabetes appears to increase risk of death for patients with acute coronary syndromes
5. Ambulatory oxygen rarely a benefit in COPD patients without resting hypoxemia
6. Restricting Blood Flow May Help Heart Bypass Patients
7. Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer
8. Study provides hope that some transplant patients could live free of antirejection drugs
9. Study provides hope that some transplant patients could live free of anti-rejection drugs
10. Longer ambulance journeys boost death risk for seriously ill patients
11. Expenses Overshadow Optimism for Kidney Failure Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... As part of their 2015 end of year ... Table Foundation (MDRTF), has gifted $10,000 to University of Chicago to support ovarian cancer ... Cundiff. , “We are honored to support a promising young investigator from Dr. Lengyel’s ...
(Date:2/10/2016)... ... February 10, 2016 , ... The ... World Molecular Imaging Congress (WMIC), will be held in New York City, NY ... “Imaging Biology…Improving Therapy.” The congress will highlight and emphasize how imaging reveals a ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Early this week, ... and raise awareness of Nestlé KITKAT as the first global confectionery brand sourced from ... cocoa farmers and the quality of their product, through activities that focus on better ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... care communications company offering education, research and medical media, has launched ... working in infectious diseases. , As the all-inclusive resource for infectious disease ...
(Date:2/10/2016)... Walton Beach, Florida (PRWEB) , ... February 10, ... ... the innovative weather-forecasting company is unveiling its revolutionary new 2.0 version at the ... platform, MetLoop has “put the power of the world's most advanced weather technology ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ... fourth quarter and full year ended December 31, 2015. ... was a transformational year for Vanda with the continued ... market approval of HETLIOZ for Non-24," said Mihael H. ... Fanapt to our U.S. product portfolio builds on this ...
(Date:2/10/2016)... , February 10, 2016 ... Analyzers (Liquid & Gas), and Spectroscopy Market by Industry (Oil ... Beverage, Pulp & Paper, Metal & Mining, and Others), ... MarketsandMarkets, the global market is expected to grow to ... of 8.6% between 2015 and 2020. Browse ...
(Date:2/10/2016)... , Feb. 10, 2016  Resolve Therapeutics, ... transformative new approaches to the treatment of lupus ... of a multiple ascending dose study in patients ... compound RSLV-132. --> ... placebo-controlled multiple ascending dose study of RSLV-132 in ...
Breaking Medicine Technology: